These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 30140875)

  • 1. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
    JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
    Socal MP; Bai G; Anderson GF
    JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
    Egilman AC; Wallach JD; Ross JS; Dhruva SS
    JAMA Intern Med; 2018 Apr; 178(4):567-569. PubMed ID: 29340562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Private expenditures on brand name prescription drugs after generic entry.
    Balaban DY; Dhalla IA; Law MR; Bell CM
    Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.